

Highly Efficient Reverse siRNA Transfection of Human Epithelial Lung Carcinoma A549 Cells Using siLentFect™ Lipid Reagent

Claudia M Litterst and Luis Ugozzoli, Bio-Rad Laboratories, Inc., Hercules, CA 94547

Introduction

A549 cells are a cellular model system widely used to study the molecular biology of allergic and inflammatory responses in lung epithelial cells. These cells represent alveolar type 2 epithelial cells and release inflammatory mediators when stimulated with type 2 helper T cells (Th2) and proinflammatory cytokines (Sekiya et al. 2000, Shankaranarayanan and Nigam 2003, Taka et al. 2008).

PP2A is a serine/threonine-specific Ca^{2+} -independent protein phosphatase. PP2A, which is expressed ubiquitously in eukaryotic cells, has been shown to promote the IL-4 signaling pathway (Woetmann et al. 2003) and is potentially involved in the regulation of allergic responses in lung epithelial cells.

Short interfering RNAs (siRNAs) are powerful tools to suppress gene expression in mammalian cells. Elbashir et al. showed that transfection of short RNA (21-mers) could induce the silencing of specific genes at a cellular level, thus providing a simpler method for the loss-of-function study compared with traditional technologies (Elbashir et al. 2001). Subsequently, J Rossi and colleagues demonstrated that 27-nt duplexes are often more effective at silencing than the corresponding 21-mer siRNAs (Kim et al. 2005).

We show here a highly efficient reverse siRNA transfection protocol for A549 cells using siLentFect lipid reagent for *GAPDH* and *PP2A* knockdown. No prior seeding of cells is required, since siRNA-lipid complexes can be directly added to cells in suspension. The simplicity of the protocol makes it suitable for high-throughput transfection. Using 27-nt siRNA duplexes, we achieved more than 97% knockdown for *GAPDH* and 93% for *PP2A*. Furthermore, we demonstrated that siLentFect lipid reagent does not impair cell viability under these conditions. We conclude that this protocol can be used in functional genomic studies to investigate the biology of allergies and inflammation.

Methods

Transfection

A549 cells (American Type Culture Collection, ATCC #CCL-185) were grown in F-12K nutrient mixture, Kaighn's modification (Invitrogen Corporation) with 10% fetal bovine serum. Transfection complexes were prepared in Opti-MEM I reduced-serum medium (Invitrogen). Human *GAPDH* siRNA and nonsilencing siRNA were used (siLentMer starter kit for human *GAPDH*, Bio-Rad Laboratories, Inc.). *PP2A* siRNA was obtained from Integrated DNA Technologies, Inc. (IDT; sequence can be obtained upon request). For transfections, varying amounts of siLentFect lipid reagent (Bio-Rad) were mixed with 100 μl Opti-MEM I medium, added to 20 pmol fluorescent nonsilencing siRNA, and incubated for 20 min at room temperature. During the incubation time, cells were prepared for transfection. They were detached by trypsinization and resuspended in growth media at 100,000–140,000 cells/ml. After the incubation, the siRNA-lipid mix and 1 ml of cell suspension were combined in 12-well tissue culture dishes, resulting in a 20 nM final siRNA concentration, and cells were cultured overnight at 37°C.

Analysis of Transfection Efficiency

RNA was extracted using an Aurum™ total RNA mini kit (Bio-Rad). cDNA was prepared with an iScript™ cDNA synthesis kit (Bio-Rad). Real-time PCR reactions were performed using iQ™ supermix on a CFX96™ real-time PCR detection system, and data were analyzed using CFX Manager™ software (all from Bio-Rad). Primers for amplification of β -actin, *GAPDH*, and *PP2A* were purchased from IDT (sequences can be obtained upon request). LDH levels in the cell culture supernatant were determined using a CytoScan LDH cytotoxicity assay kit according to the manufacturer's recommendations (G-Biosciences).

Results

We show here the optimization of siRNA transfection conditions for A549 cells. This was carried out by varying the amount of lipid transfection reagent to achieve maximal siRNA uptake without affecting cell viability. As recommended for 12-well dishes in the siLentFect™ Lipid Reagent Instruction Manual, we tested the range of 0.5–4 μ l of lipid. We transfected nonsilencing siRNA using a reverse transfection protocol that involves simultaneous transfection and plating of the cells. All transfections were carried out at a 20 nM final siRNA concentration.

Sixteen hours after transfection, we assessed cytotoxicity by measuring LDH release in cell culture supernatants. As shown in Figure 1A, 0.5 and 1 μ l of lipid resulted in similar levels of LDH in the culture media as in the nontransfected control cells, indicating that these amounts of lipid did not impair viability of the cells. However, 2 and 4 μ l of lipid resulted in increased LDH release. We also performed experiments 48 and 72 hr post-transfection with 1 μ l of lipid, and did not observe any increase in cytotoxicity when this amount of lipid was used (data not shown).

To quantify the knockdown of gene expression, we transfected a *GAPDH* siRNA and a nonsilencing control RNA using 0.5, 1, and 2 μ l of lipid. Total RNA was prepared 16 hr after transfection, reverse transcribed, and *GAPDH* mRNA levels were determined by real-time PCR. Depending on the amount of lipid used, *GAPDH* gene expression was knocked down to 0.4–7.2% of the levels in control samples (92.8–99.6% knockdown, Figure 1B). One microliter of lipid resulted in 97% knockdown of *GAPDH* expression, an amount of lipid that does not impair viability. In summary, siLentFect lipid reagent can be used for highly efficient reverse siRNA transfection of A549 cells without impairing the viability of the cells.

To confirm that the described siRNA transfection protocol can be used for the knockdown of scientifically relevant genes in A549 cells, we tested transfection of an siRNA targeting PP2A, a potential regulator of IL-4 signaling in A549 cells. Cells were transfected with a PP2A siRNA or a nonsilencing RNA control using 1 μ l of lipid, which proved to be nontoxic for cells (see Figure 1A). As shown in Figure 2, we achieved 93% knockdown (7% remaining expression) for PP2A.





Fig. 1. Optimization of siLentFect lipid reagent volume for siRNA transfection in A549 cells. A549 cells were transfected with nonsilencing siRNA or a *GAPDH* siRNA and a nonsilencing control siRNA using the indicated amount of siLentFect lipid reagent (20 nM final siRNA concentration). Cells were analyzed 16 hr after transfection. **A**, percentage LDH release; **B**, β -actin and *GAPDH* mRNA levels: β -actin (reference gene) expression in control samples (■), and in *GAPDH* siRNA-transfected samples (■); *GAPDH* levels in *GAPDH* siRNA-transfected samples using 0.5 μ l (■), 1 μ l (■), and 2 μ l (■) siLentFect lipid reagent, and in control siRNA-transfected samples (0.5, 1, and 2 μ l of lipid reagent) (■). RFU, relative fluorescence units.



siRNA	C _T Target	C _T Reference	Δ C _T	ΔΔ C _T	Knockdown, %
PP2A—a	20.71	11.94	8.77	3.80	92.81
PP2A—b	20.66	11.87	8.79	3.71	92.34
Control—a	16.77	11.80	4.97		
Control—b	16.87	11.79	5.08		

Fig. 2. Efficient knockdown of PP2A expression in A549 cells using siLentFect lipid reagent. A549 cells were transfected with a PP2A siRNA and a nonsilencing control siRNA (20 nM final siRNA concentration) in duplicate (samples a and b). PP2A and *GAPDH* (reference gene) mRNA levels were determined 16 hr after transfection. Chart shows expression of *GAPDH* in control samples (■) and in PP2A siRNA–transfected samples (■) and PP2A expression in control samples (■) and in PP2A siRNA–transfected samples (■). RFU, relative fluorescence units.

Conclusions

We designed a protocol for rapid, highly efficient siRNA transfection of A549 cells. This simple protocol can be easily adapted for high-throughput transfections. We achieved 97% knockdown for *GAPDH* and 93% for PP2A without impairing cell viability. Furthermore we showcased that our protocol is suitable for functional studies to identify and characterize new regulators of inflammatory responses in A549 cells.

References

- Elbashir SM et al. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411, 494-498.
- Kim DH et al. (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. *Nat Biotechnol* 23, 222-226.
- Sekiya T et al. (2000). Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. *J Immunol* 165, 2205-2213.
- Shankaranarayanan P and Nigam S (2003). IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor gamma transcription factor. *J Immunol* 170, 887-894.
- Taka E et al. (2008). Post-transcriptional silencing of CCR3 downregulates IL-4 stimulated release of eotaxin-3 (CCL26) and other CCR3 ligands in alveolar type II cells. *Cytokine* 44, 342-351.
- Woetmann A et al. (2003). Protein phosphatase 2A (PP2A) regulates interleukin-4-mediated STAT6 signaling. *J Biol Chem* 278, 2787-2791.

The ATCC trademark and ATCC catalog number CCL-185 are trademarks of the American Type Culture Collection. CytoScan is a trademark of Geno Technology, Inc. Opti-MEM is a trademark of Invitrogen Corporation.

Practice of the patented 5' Nuclease Process requires a license from Applied Biosystems. The purchase of iQ supermix includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser's own internal research when used with the separate purchase of Licensed Probe. No other patent rights are conveyed expressly, by implication, or by estoppel. Further information on purchasing licenses may be obtained from the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA.

Bio-Rad's real-time thermal cyclers are licensed real-time thermal cyclers under Applied's United States Patent 6,814,934 B1 for use in research, human in vitro diagnostics, and all other fields except veterinary diagnostics.

Bio-Rad's real-time thermal cyclers are covered by one or more of the following U.S. patents or their foreign counterparts owned by Eppendorf AG: U.S. Patent Nos. 6,767,512 and 7,074,367.

Information in this tech note was current as of the date of writing (2009) and not necessarily the date this version (rev A, 2009) was published.



**Bio-Rad
Laboratories, Inc.**

Life Science
Group

Web site www.bio-rad.com **USA** 800 4BIORAD **Australia** 61 02 9914 2800 **Austria** 01 877 89 01 **Belgium** 09 385 55 11 **Brazil** 55 21 3237 9400
Canada 905 364 3435 **China** 86 21 6426 0808 **Czech Republic** 420 241 430 532 **Denmark** 44 52 10 00 **Finland** 09 804 22 00 **France** 01 47 95 69 65
Germany 089 318 84 0 **Greece** 30 210 777 4396 **Hong Kong** 852 2789 3300 **Hungary** 36 1 455 8800 **India** 91 124 4029300 **Israel** 03 963 6050
Italy 39 02 216091 **Japan** 03 6361 7000 **Korea** 82 2 3473 4460 **Mexico** 52 555 488 7670 **The Netherlands** 0318 540666 **New Zealand** 0508 805 500
Norway 23 38 41 30 **Poland** 48 22 331 99 99 **Portugal** 351 21 472 7700 **Russia** 7 495 721 14 04 **Singapore** 65 6415 3188 **South Africa** 27 861 246 723
Spain 34 91 590 5200 **Sweden** 08 555 12700 **Switzerland** 061 717 95 55 **Taiwan** 886 2 2578 7189 **United Kingdom** 020 8328 2000
